U-47700
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
U-47700 — Pink, U4 — is a synthetic opioid of the benzamide class. It is 7.5 to 12 times more potent than morphine, derived from a structurally distinct chemical scaffold.[1] It activates opioid receptors in the brain and spinal cord, suppressing pain and slowing breathing.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, heroin, fentanyl +4 moremorphine, heroin, fentanyl, oxycodone, methadone, buprenorphine, all opioids show less
Jacob Szmuszkovicz synthesized it in 1978 searching for new opioid painkillers; it was never approved for medical use.[3][4] It appeared on illicit markets in 2015 and spread across North America and Europe, linked to hundreds of overdose deaths. Emergency scheduling followed in late 2016; international control came in March 2017.
Subjective effects include euphoria, pain suppression, heavy sedation, and a warm dissolution of anxiety. The experience is a compressed opioid arc — an intense rush of warmth and pain dissolution that fades within hours, driving a compulsive compulsive redosing urge. Nausea, slowed breathing, and mental fog are characteristic unwanted effects.
U-47700 produces rapid physical dependence, and fatal concentrations as low as 17 ng/mL[5] represent one of the narrowest effect-to-death margins in the opioid class. Most deaths involved combining it with benzodiazepines or fentanyl, stacking respiratory depression beyond what either produces alone.[6] No controlled human studies exist; the evidence comes from animal pharmacology, forensic cases, and computational modeling.
History[edit]
Discovery
Jacob Szmuszkovicz synthesized U-47700 at The Upjohn Company in 1978 as part of a program to develop selective opioid painkillers from a new chemical family.[3] The compound was patented but never moved into clinical development.[4]
Emergence and crisis
It sat unknown for nearly four decades before appearing on a Finnish internet drug forum in March 2015.[7] By 2016 it circulated widely under the names "Pink" and "U4," appeared in counterfeit oxycodone tablets, and was identified as a component of "gray death" — a polydrug mixture containing heroin, fentanyl, and carfentanil.[4][8] It was detected at the autopsy of the musician Prince in April 2016.
Scheduling
The DEA emergency-scheduled U-47700 as Schedule I in November 2016, citing at least 46 confirmed deaths.[9][10] The United Nations placed it under Schedule I of the 1961 Single Convention in March 2017.[11] The United Kingdom, Canada, and Finland enacted national controls within the same period.
The designation "U-47700" follows the Upjohn laboratory numbering system — "U" is the company prefix, 47700 the compound number.[4] On illicit markets it earned the names "Pink" and "Pinky" — references to its pale powder appearance — and "Pink heroin," a misnomer that positioned it as a heroin substitute.[8]
Chemistry[edit]
Structural class
U-47700 belongs to the benzamide class — a family of opioids built on a different scaffold than morphine or fentanyl.[4] Its molecular formula is C₁₆H₂₂Cl₂N₂O (molecular weight 329.3 g/mol).[11] Related compounds include AH-7921 and U-50488, both from the same Upjohn research program.
Molecular structure
Two chlorine atoms on the benzene ring are essential for potency — removing them sharply reduces opioid binding strength.[1] The molecule's fat-solubility allows rapid brain penetration, which accounts for its 7.5 to 12-fold potency advantage over morphine in practice. The pharmacologically active form is the trans stereoisomer; a naming discrepancy exists in the literature but both designations refer to the same molecule.[4][12]
Pharmacology[edit]
Mechanism of action
U-47700 activates mu-opioid receptors as a full agonist — the same pathway used by morphine, heroin, and fentanyl.[8][13] Receptor activation suppresses pain signals and depresses neuronal firing, producing the full classical opioid spectrum: analgesia, euphoria, sedation, respiratory depression, constipation, and pupil constriction.
U-47700 produces maximum receptor activation comparable to fentanyl.[2] All effects are completely reversed by naloxone.[2][14] It is strongly selective for mu-opioid receptors over other opioid receptor types,[1] consistent with the classical profile of analgesia and euphoria rather than the dysphoric effects linked to other opioid receptor types.
Pharmacokinetics
No controlled human pharmacokinetic studies exist. The body breaks down U-47700 by removing its methyl groups, producing N-desmethyl-U-47700 — the primary metabolite, which retains some opioid activity[15][1] and is the main marker detected in urine during forensic testing.[16] Standard drug screens cannot detect U-47700; specialized mass spectrometry is required.[5][17]
Neuroscience[edit]
Where it acts
U-47700 activates mu-opioid receptors in two key brain systems. In the reward circuit, activation releases dopamine, driving euphoria and reinforcement.[8] In the brain's pain-suppression system, activation in the brainstem and spinal cord blocks pain signals, producing analgesia.[1]
The lethal mechanism — respiratory depression — originates in brainstem neurons that regulate breathing rate and depth. The analgesic dose and the dose that stops breathing sit dangerously close together, a feature shared with fentanyl and other potent opioids.
Why short duration matters
U-47700's rapid onset and short duration drive compulsive use. Short-acting opioids produce sharp dopamine spikes that fade quickly — a pattern that fires the brain's motivational "wanting" circuits more than it sustains pleasure.[8] Each rush-and-fadeout cycle accelerates psychological dependence faster than longer-acting opioids like methadone.
Several fundamental questions remain unanswered. Whether U-47700 favors one intracellular pathway over another at the mu-opioid receptor — with direct safety implications — has not been tested. An experimental vaccine that blocks U-47700 from reaching the brain has shown efficacy in rodents,[12] but its effects in opioid-dependent individuals remain uncharacterized.
Subjective Effects[edit]
The U-47700 experience is defined by compression: a potent opioid effect packed into a short window. A fast-arriving rush of warmth and pain dissolution gives way to heavy sedation, then fades — leaving the cycle poised to restart. This creates a pull toward redosing stronger than longer-acting opioids produce.
Relative to morphine, U-47700 produces qualitatively similar effects but in a compressed arc. Compared to fentanyl, onset is slightly less abrupt but duration is similarly brief — placing U-47700 in the same pharmacokinetic territory that makes short-acting opioids disproportionately reinforcing.
Effect Grid
At 6–8 mg insufflated, the full mu-opioid effect profile is expressed. Euphoria is pronounced — a pervasive warmth and deep contentment that dominates the experience. Anxiety suppression is strong, cognitive euphoria is marked, and thought deceleration produces a characteristic mental stillness. Emotional suppression flattens affective range.
Tactile euphoria and bodily heaviness are prominent. Sedation is significant, with drowsiness or early nodding possible at the upper end. Pupil constriction is marked. Muscle relaxation is noticeable. Constipation and nausea may occur. Respiratory depression is measurable but not typically life-threatening in isolation.
Compulsive redosing urge becomes strong as the 2–3 hour effects window closes. Accurate dosing within this narrow 2 mg range is safety-critical.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Body high · Constipation · Bodily heaviness · Tactile euphoria · Muscle relaxation · Breathing alteration · Nausea · Dizziness · Physical fatigue · Spontaneous body sensations · Excessive sweating · Dry mouth · Tingling / electric sensations · Sexual arousal suppression · Vomiting · Yawning · Bodily dissociation
Muscle relaxation · Breathing alteration · Nausea · Dizziness · Physical fatigue · Spontaneous body sensations · Excessive sweating · Dry mouth · Tingling / electric sensations · Sexual arousal suppression · Vomiting · Yawning · Bodily dissociation
Analysis suppression · Focus suppression · Information processing suppression · Thought deceleration · Language suppression · Motivation suppression · Confusion · Thought disorganization · Memory suppression · Memory fragmentation · Amnesia · Delirium
Thought deceleration · Language suppression · Motivation suppression · Confusion · Thought disorganization · Memory suppression · Memory fragmentation · Delirium
Social disconnection · Depersonalization · Derealization · Cognitive disconnection
Timeline
Initial opioid effects emerge within minutes — faint warmth spreading from nasal passages, subtle mood lift, first hints of anxiety suppression.
Rapid intensification of euphoria, sedation, and analgesia. Pupil constriction becomes visible. Body high and tactile euphoria build noticeably.
Maximum opioid effects — pronounced euphoria, strong sedation, marked analgesia, and significant respiratory depression. Cognitive euphoria and emotional suppression are at their fullest. Nodding may occur at higher doses.
Effects diminish relatively rapidly. Euphoria fades first while sedation lingers. Compulsive redosing urge peaks as the subjective reward recedes.
Residual sedation, mild cognitive slowing, and possible early withdrawal-like dysphoria in repeat users. Craving may persist.
⚠ Do not drive or operate machinery for at least 6 hours after use — residual sedation and impaired reaction time persist beyond subjective offset.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 1.5 weeks
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · heroin · fentanyl
Toxicity
Acute toxicity
U-47700 has high acute toxicity. The dose that produces respiratory depression sits close to the dose that produces pain suppression, leaving almost no margin between effect and death.[4] Fatal blood concentrations in forensic cases range from 17 ng/mL[5] to over 2,000 ng/mL[6] — the wide spread reflects differences in tolerance, co-ingested substances, and postmortem redistribution.
Death in all documented cases follows the same path: breathing slows and stops, depriving the brain of oxygen, leading to cardiac arrest — the mechanism common to all μ-opioid overdoses.
Fatality epidemiology
Most documented deaths occurred in 2016–2017, before international scheduling took effect. German forensic data identified 26 fatalities (25 male, mean age 34), over half involving other novel psychoactive substances.[6] US surveillance found U-47700 in 40 opioid overdose deaths across 10 states in late 2016 — 60% also tested positive for fentanyl.[18]
Finnish authorities confirmed 10 deaths,[7] and at least 46 US deaths were cited as grounds for emergency scheduling.[9] Canadian polysubstance fatalities included co-detection with furanylfentanyl.[19] The overwhelming majority involved combination with other depressants.[6][7]
Selected case reports
One fatal case documented combined insufflation with alprazolam, attributed to combined toxicity.[20] The first documented intravenous fatality confirmed high-purity powder and provided novel tissue distribution data.[21] One individual was revived at the scene but died six days later in intensive care, with co-detected mitragynine.[22] The first published near-fatal case confirmed that naloxone reversed the opioid toxidrome.[14]
Detection limitations
U-47700 is invisible to standard hospital and forensic drug screens. Identification requires specialized mass spectrometry.[5][17][23] This limitation contributed to under-detection during the initial wave of fatalities and remains a risk factor wherever U-47700 may be present.
Naloxone reversibility
U-47700's effects are fully reversible by naloxone. In the first published near-fatal case, naloxone restored breathing and consciousness.[14] Given U-47700's high potency, standard doses (0.4 mg) may be insufficient — multiple doses or higher initial doses may be required.[24] Titrate to adequate breathing, not full consciousness.
Psychological risks
The combination of rapid onset, intense euphoria, and short duration creates strong compulsive redosing — consistently reflected in user reports and forensic cases where multiple doses preceded death.
At higher doses, cognitive slowing, sedation, and confusion impair decision-making during intoxication, increasing accidental overdose risk through continued redosing. Withdrawal produces anxiety, irritability, depression, and craving — and given U-47700's short duration, symptoms may emerge within hours of last use.
Tolerance and dependence
U-47700 is expected to produce rapid tolerance through receptor desensitization and downstream changes in brain reward circuits, shared by all full mu-opioid agonists. Cross-tolerance with all other opioids — morphine, heroin, fentanyl, oxycodone — is expected given the shared receptor mechanism.[8] inferred
Physical dependence produces a characteristic withdrawal syndrome: autonomic hyperactivity, gastrointestinal distress, muscle pain, insomnia, and craving. Given U-47700's short duration, withdrawal onset may be more rapid than with longer-acting opioids. Standard opioid therapies (buprenorphine, methadone, naltrexone) would theoretically apply, but no case reports document their use for U-47700 specifically. inferred
Drug interactions
The majority of U-47700 fatalities involved polysubstance use. Combining it with any central nervous system depressant carries risk of fatal respiratory depression. No specific interaction studies exist; all assessments derive from published case reports and pharmacological class inference.
Additive respiratory depression
- Benzodiazepines: Multiple fatal cases document combined use with both designer and classical benzodiazepines.[25][20] This combination is documented as directly lethal.
- Alcohol: Produces additive respiratory and central nervous system depression.
- GHB/GBL: Both are potent depressants that compound respiratory depression with opioids.
- Other opioids: Additive mu-opioid activation stacks respiratory depression. Tramadol additionally carries seizure risk.
Metabolic interactions
U-47700 is broken down primarily by the CYP3A4 liver enzyme. Strong inhibitors of this enzyme — ketoconazole, clarithromycin, ritonavir — could substantially raise U-47700 blood levels, effectively increasing the delivered dose. Enzyme inducers (rifampicin, carbamazepine) could reduce levels, potentially triggering withdrawal in dependent individuals. inferred
Dissociative combinations
Ketamine produces respiratory depression at anesthetic doses; combining it with opioids increases this risk. The interaction between U-47700 and PCP has not been characterized. citation needed
Contraindications
No formal contraindication studies specific to U-47700 have been conducted. The following are inferred from its pharmacological profile: inferred
- Respiratory compromise: Pre-existing breathing impairment (chronic obstructive pulmonary disease, asthma, sleep apnea) dramatically lowers the fatal dose threshold.
- Concurrent depressant use: Co-administration with benzodiazepines, alcohol, barbiturates, GHB/GBL, or other opioids is contraindicated based on documented fatality data.
- Liver impairment: Reduced metabolic clearance increases drug exposure and overdose risk.
- Opioid-naive individuals: The narrow therapeutic index makes U-47700 exceptionally dangerous without opioid tolerance. Fatal concentrations as low as 17 ng/mL have been documented.[5]
- Pregnancy: All mu-opioid agonists carry risk of neonatal opioid withdrawal syndrome. No U-47700-specific reproductive data exist. safety citation needed
- CYP3A4 inhibitor co-administration: Concurrent use of potent CYP3A4 inhibitors increases blood levels and overdose risk.
Harm Reduction[edit]
Forms & Identification
U-47700 is not detected by standard immunoassay drug screens or fentanyl test strips — a negative result on either test does not confirm the substance is absent. The only reliable identification method is laboratory mass spectrometry, unavailable to most users.
U-47700 has appeared in counterfeit pharmaceutical tablets[4] and polysubstance mixtures like "gray death." Any unregulated opioid powder or pressed pill could contain it. Reagent testing can help distinguish broad substance classes but cannot reliably identify or quantify U-47700. The narrow margin between an active and fatal dose makes this uncertainty especially dangerous.
Guidelines
- Test every sample with available reagent kits, understanding their limitations for this compound.
- Weigh doses with a milligram-scale balance. Never estimate by eye.
- Use volumetric dosing (dissolving a weighed amount in a measured volume of liquid) to reduce hotspot risk in powder.
- Start with the lowest reported threshold dose, especially if opioid-naive or tolerance status is uncertain.
- Set a firm redosing limit before the session. The compulsive compulsive redosing urge is the defining behavioral risk.
- Always have naloxone immediately accessible — and ensure the observer knows how to administer it.
- Never combine with benzodiazepines, alcohol, other opioids, or any central nervous system depressant.
- Never use alone.
Set & Setting
U-47700's short duration and intense rush drive compulsive redosing. Using alone removes the only safeguard against overdose if consciousness is lost. A sober observer with access to naloxone is the single most effective harm reduction measure for this compound.
The environment should allow the user to lie in the recovery position if sedation becomes heavy. Avoid settings where loss of consciousness could result in injury — near water, at height, or while operating machinery.
Aftercare & integration. After any U-47700 session, monitor for delayed respiratory depression — especially if multiple doses were taken or other depressants were co-ingested. At least one documented fatality occurred six days after initial resuscitation.[22]
Hydrate, eat when appetite returns, and prioritize sleep. Compulsive redosing during a session is a signal: short-acting opioids build psychological dependence quickly with each compressed use cycle.
Use motivated by chronic pain or emotional distress warrants exploring non-opioid alternatives with a healthcare provider.
Recovery & Support
U-47700 dependence is pharmacologically identical to other opioid dependencies and responds to the same evidence-based treatments. Opioid agonist therapy (buprenorphine or methadone) stabilizes the μ-opioid system and reduces craving. Naltrexone blocks receptor activation and is an option after full detoxification.
Given U-47700's short duration, withdrawal onset may be rapid — within hours of last use. Medical supervision during withdrawal reduces both suffering and the risk of relapse-driven overdose, which is highest in the days immediately after cessation when tolerance has dropped but craving has not.
Peer support programs and addiction counseling complement pharmacotherapy. No U-47700-specific treatment protocols exist, but standard opioid use disorder treatment pathways apply.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
The signs of U-47700 overdose are identical to other opioid overdoses: breathing slows or stops, lips and fingertips turn blue or gray, the person becomes unresponsive, and pupils constrict to pinpoints. Loud snoring or gurgling in an unconscious person signals airway obstruction and imminent respiratory failure.
Immediate steps
- 1. Call emergency services immediately.
- 2. Administer naloxone if available. Standard doses (0.4 mg) may be insufficient for U-47700 — administer additional doses every 2–3 minutes if breathing does not improve.[24]
- 3. Place the person in the recovery position (on their side) to prevent aspiration.
- 4. Stay with them. U-47700's duration may outlast naloxone, and breathing can stop again.
- 5. Do not induce vomiting. Do not leave the person alone.
What to tell the dispatcher
State that the person is not breathing or breathing very slowly, that opioid overdose is suspected, the substance name if known, the approximate time of last dose, and whether naloxone has been given. Good Samaritan laws in many jurisdictions protect callers who report overdoses from drug-related prosecution.
Reversal agent
Naloxone reverses U-47700 overdose.[14][2] Multiple doses may be necessary. Titrate to adequate breathing, not full consciousness — waking an opioid-dependent person too abruptly can precipitate severe withdrawal.
Legal Status[edit]
U-47700 is internationally controlled under Schedule I of the 1961 Single Convention on Narcotic Drugs, placed there in March 2017[11] — an unusually fast path from first market detection in 2015 to international control, driven by a concentrated wave of deaths across multiple countries.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Emergency placement November 14, 2016; permanent Schedule I April 20, 2018. At least 46 confirmed deaths cited as basis for emergency action.[10][9] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under the 2017 Amendment Order, effective May 31, 2017.[26] |
| International | Schedule I (1961 Single Convention) | Placed at the 60th session of the UNCND, March 2017.[11] |
| Canada | Schedule I (CDSA) | Added to Schedule I of the Controlled Drugs and Substances Act, December 2017.[27] |
| Finland | National control | Nationally controlled from November 2016.[7] |
| Germany | Anlage I (BtMG) | Controlled under the Narcotics Act (Betaeubungsmittelgesetz), circa 2016. citation needed |
| New Zealand | Class A (Misuse of Drugs Act 1975) | Classified December 2022. citation needed |
Legal classifications change over time. The information above is for harm reduction reference only and is not legal advice.
references
- [1]
- [2] ^abcdBaumann MH, Majumdar S, Le Rouzic V, et al. (2018) Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace — Neuropharmacology doi:10.1016/j.neuropharm.2017.08.016
- [3]
- [4]
- [5]
- [6] ^abcdFels H, Lottner-Nau S, Sax T, Roider G, Graw M, Auwaerter V, Musshoff F (2019) Postmortem concentrations of the synthetic opioid U-47700 in 26 fatalities associated with the drug — Forensic Science International doi:10.1016/j.forsciint.2019.04.010